BioAtla (BCAB) Change in Interest Receivables (2020 - 2021)
BioAtla (BCAB) posted quarterly Change in Interest Receivables of -$2000.0 for Q2 2021, up 99.83% year-over-year from -$1000.8 in Q2 2020, and down 100.0% quarter-over-quarter from -$1000.0 in Q1 2021.
BioAtla (BCAB) Change in Interest Receivables (2020 - 2021) Analysis & Trends
BioAtla's Change in Interest Receivables history runs 2 years deep, the most recent figure standing at -$2000.0 for Q2 2021.
- In Q2 2021, Change in Interest Receivables rose 99.83% year-over-year to -$2000.0; the TTM figure through Mar 2022 stood at -$2000.0 (up 99.84% YoY), while the FY2021 annual figure was -$3000.0, up 99.65% from the prior year.
- Change in Interest Receivables for Q2 2021 stood at -$2000.0, down from -$1000.0 in the prior quarter.
- The five-year high for Change in Interest Receivables was $379000.0 in Q1 2020, with the low at -$1.2 million in Q2 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Interest Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | BioAtla | 5.41 Mn | 5.41 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | -2,000.00 |
| Mar 31, 2021 | -1,000.00 |
| Dec 31, 2020 | -2,000.00 |
| Sep 30, 2020 | -49,000.00 |
| Jun 30, 2020 | -1.19 Mn |
| Mar 31, 2020 | 379,000.00 |